Molecular characterization by immunocytochemistry of lung adenocarcinoma on cytology specimens

Acta Cytologica

Volumn 56, Issue 6, 2012, Pages 603-610

  Moreira, Andre L ^a   Hasanovic, Adnan ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Adenocarcinoma; ALK; EGFR; Immunocytochemistry; Lung

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; MUTANT PROTEIN;

ADVANCED CANCER; CANCER PATIENT; CANCER STAGING; CYTOPATHOLOGY; EML4 ALK FUSION GENE; FUSION GENE; GENE MUTATION; GENE REARRANGEMENT; HUMAN; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG BIOPSY; PRIORITY JOURNAL; REVIEW;

EID: 84870711129     PISSN: 00015547     EISSN: None     Source Type: Journal    
DOI: 10.1159/000339794     Document Type: Review

References (76)

1. Jemal A, Siegel R, Xu J, et al: Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277-300.
2. Travis WD, Rekhtman N, Riley GJ, et al: Pathologic diagnosis of advanced lung cancer based on small biopsies and cytology: a paradigm shift. J Thorac Oncol 2010; 5: 411-414.
3. Johnson DH, Fehrenbacher L, Novotny WF, et al: Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004; 22: 2184-2191. (Pubitemid 41095154)
4. Sandler A, Gray R, Perry MC, et al: Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355: 2542-2550. (Pubitemid 44917502)
5. Scagliotti G, Hanna N, Fossella F, et al: The differential efficacy of pemetrexed according to NSCLC histology: a review of two phase III studies. Oncologist 2009; 14: 253-263.
6. Travis WD, Brambilla E, Noguchi M, et al: International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 2011; 6: 244-285.
7. Edwards SL, Roberts C, McKean ME, et al: Preoperative histological classification of primary lung cancer: accuracy of diagnosis and use of the non-small cell category. J Clin Pathol 2000; 53: 537-540. (Pubitemid 30432112)
8. Rekhtman N, Ang DC, Sima CS, Travis WD, Moreira AL: Immunohistochemical algorithm for differentiation of lung adenocarcinoma and squamous cell carcinoma based on large series of whole-tissue sections with validation in small specimens. Mod Pathol 2011; 10: 1348-1359.
9. Mukhopadhyay S, Katzenstein AL: Subclassification of non-small cell lung carcinomas lacking morphologic differentiation on biopsy specimens: utility of an immunohistochemical panel containing TTF-1, napsin A, p63, and CK5/6. Am J Surg Pathol 2011; 35: 15-25.
10. Nicholson AG, Gonzalez D, Shah P, et al: Refining the diagnosis and EGFR status of nonsmall cell lung carcinoma in biopsy and cytologic material, using a panel of mucin staining, TTF-1, cytokeratin 5/6, and P63, and EGFR mutation analysis. J Thorac Oncol 2010; 5: 436-441.
11. Pao W, Girard N: New driver mutations in non-small-cell lung cancer. Lancet Oncol 2011; 12: 175-180.
12. Lynch TJ, Bell DW, Sordella R, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350: 2129-2139. (Pubitemid 38637993)
13. Paez JG, Jänne PA, Lee JC, Tracy S, et al: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304: 1497-1500. (Pubitemid 38720929)
14. Pao W, Miller V, Zakowski M, Doherty J, et al: EGF receptor gene mutations are common in lung cancers from 'never smokers' and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004; 101: 13306-13311. (Pubitemid 39209661)
15. Soda M, Choi YL, Enomoto M, Takada S, et al: Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007; 448: 561-566. (Pubitemid 47206930)
16. Rikova K, Guo A, Zeng Q, Possemato A, et al: Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 2007; 131: 1190-1203. (Pubitemid 350235027)
17. Pao W, Chmielecki J: Rational, biologically based treatment of EGFR-mutant nonsmall-cell lung cancer. Nat Rev Cancer 2010; 10: 760-774.
18. Felip E, Gridelli C, Baas P, et al: Metastatic non-small-cell lung cancer: consensus on pathology and molecular tests, first-line, second-line, and third-line therapy-1st ESMO Consensus Conference in Lung Cancer; Lugano 2010. Ann Oncol 2011; 22: 1507-1519.
19. Ellis PM, Blais N, Soulieres D, et al: A systematic review and Canadian consensus recommendations on the use of biomarkers in the treatment of non-small cell lung cancer. J Thorac Oncol 2011; 6: 1379-1391.
20. Molina JR, Adjei AA, Jett JR: Advances in chemotherapy of non-small cell lung cancer. Chest 2006; 130: 1211-1219. (Pubitemid 44583755)
21. Fukuoka M: Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 2003; 21: 2237-2246. (Pubitemid 46621858)
22. Kris MG, Natale RB, Herbst RS, et al: Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003; 290: 2149-2158. (Pubitemid 37432975)
23. Miller VA, Kris MG, Shah N, et al: Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. J Clin Oncol 2004; 22: 1103-1109. (Pubitemid 41095044)
24. Sharma SV, Bell DW, Settleman J, et al: Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 2007; 7: 169-181.
25. Sequist LV, Bell DW, Lynch TJ, et al: Molecular predictors of response to epidermal growth factor receptor antagonists in nonsmall-cell lung cancer. J Clin Oncol 2007; 25: 587-595. (Pubitemid 350002967)
26. Li AR, Chitale D, Riely GJ, et al: EGFR mutations in lung adenocarcinomas. J Mol Diagn 2008; 10: 242-248.
27. Pao W, Ladanyi M: Epidermal growth factor receptor mutation testing in lung cancer: searching for the ideal method. Clin Cancer Res 2007; 13: 4954-4955. (Pubitemid 47502057)
28. da Cunha Santos G, Saieg MA, Geddie W, Leighl N: EGFR gene status in cytological samples of non-small cell lung carcinoma: controversies and opportunities. Cancer Cytopathol 2011; 119: 80-91.
29. Herth F, Becker HD, Manegold C, et al: Endobronchial ultrasound (EBUS)-assessment of a new diagnostic tool in bronchoscopy for staging of lung cancer. Onkologie 2001; 24: 151-154. (Pubitemid 32449011)
30. Yasufuku K: Real-time endobronchial ultrasound-guided transbronchial needle aspiration of mediastinal and hilar lymph nodes. Chest 2004; 126: 122-128. (Pubitemid 38943127)
31. Wallace MB, Pascual JM, Raimondo M, et al: Minimally invasive endoscopic staging of suspected lung cancer. JAMA 2008; 299: 540-546. (Pubitemid 351214251)
32. Detterbeck FC, Jantz MA, Wallace M, et al: Invasive mediastinal staging of lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007; 132: 202S-220S. (Pubitemid 47502808)
33. Rekhtman N, Brandt SM, Sigel CS, et al: Suitability of thoracic cytology for new therapeutic paradigms in non-small cell lung carcinoma: high accuracy of tumor subtyping and feasibility of EGFR and KRAS molecular testing. J Thorac Oncol 2011; 6: 451-458.
34. Pan Q, Pao W, Ladanyi M: Rapid polymerase chain reaction-based detection of epidermal growth factor receptor gene mutations in lung adenocarcinomas. J Mol Diagn 2005; 7: 396-403. (Pubitemid 41149655)
35. Lozano MD, Zulueta JJ, Echeveste JI, et al: Assessment of epidermal growth factor receptor and K-ras mutation status in cytological stained smears of non-small cell lung cancer patients: correlation with clinical outcomes. Oncologist 2011; 16: 877-885.
36. Smouse JH, Cibas ES, Jänne PA, et al: EGFR mutations are detected comparably in cytologic and surgical pathology specimens of nonsmall cell lung cancer. Cancer 2009; 117: 67-72.
37. Schuurbiers OC, Looijen-Salamon MG, Ligtenberg MJ, et al: A brief retrospective report on the feasibility of epidermal growth factor receptor and KRAS mutation analysis in transesophageal ultrasound-and endobronchial ultrasound-guided fine needle cytological aspirates. J Thorac Oncol 2010; 5: 1664-1667.
38. Matsuno Y, Ohe Y, Furuta K, et al: Detection of EGFR mutations in archived cytologic specimens of non-small cell lung cancer using high-resolution melting analysis. Am J Clin Pathol 2006; 126: 608-615. (Pubitemid 44498512)
39. Boldrini L, Gisfredi S, Ursino S, et al: Mutational analysis in cytological specimens of advanced lung adenocarcinoma: a sensitive method for molecular diagnosis. J Thorac Oncol 2007; 2: 1086-1090. (Pubitemid 350307900)
40. Smith GD, Chadwick BE, Willmore-Payne C, et al: Detection of epidermal growth factor receptor gene mutations in cytology specimens from patients with non-small cell lung cancer utilising high-resolution melting amplicon analysis. J Clin Pathol 2008; 61: 487-493. (Pubitemid 351518232)
41. Savic S, Tapia C, Grilli B, et al: Comprehensive epidermal growth factor receptor gene analysis from cytological specimens of nonsmall-cell lung cancers. Br J Cancer 2007; 98: 154-160.
42. Garcia-Olive I, Monso E, Andreo F, et al: Endobronchial ultrasound-guided transbronchial needle aspiration for identifying EGFR mutations. Eur Respir J 2009; 35: 391-395.
43. Akagi K, Sakai H, Sudo J, et al: Simple method to detect important epidermal growth factor receptor gene mutations with bronchoscopic specimens of lung cancer patients for gefitinib treatment. Target Oncol 2007; 2: 145-151.
44. Hlinkova K, Babal P, Berzinec P, et al: Rapid and efficient detection of EGFR mutations in problematic cytologic specimens by highresolution melting analysis. Mol Diagn Ther 2011; 15: 21-29.
45. Yu J, Kane S, Wu J, et al: Mutation-specific antibodies for the detection of EGFR mutations in non-small-cell lung cancer. Clin Cancer Res 2009; 15: 3023-3028.
46. Brevet M, Arcila M, Ladanyi M: Assessment of EGFR mutation status in lung adenocarcinoma by immunohistochemistry using antibodies specific to the two major forms of mutant EGFR. J Mol Diagn 2010; 12: 169-176.
47. Kawahara A, Yamamoto C, Nakashima K, et al: Molecular diagnosis of activating EGFR mutations in non-small cell lung cancer using mutation-specific antibodies for immunohistochemical analysis. Clin Cancer Res 2010; 16: 3163-3170.
48. Kitamura A, Hosoda W, Sasaki E, et al: Immunohistochemical detection of EGFR mutation using mutation-specific antibodies in lung cancer. Clin Cancer Res 2010; 16: 3349-3355.
49. Kato Y, Peled N, Wynes MW, et al: Novel epidermal growth factor receptor mutationspecific antibodies for non-small cell lung cancer: immunohistochemistry as a possible screening method for epidermal growth factor receptor mutations. J Thorac Oncol 2010; 5: 1551-1558.
50. Kozu Y, Tsuta K, Kohno T, et al: The usefulness of mutation-specific antibodies in detecting epidermal growth factor receptor mutations and in predicting response to tyrosine kinase inhibitor therapy in lung adenocarcinoma. Lung Cancer 2011; 73: 45-50.
51. Nakamura H, Mochizuki A, Shinmyo T, et al: Immunohistochemical detection of mutated epidermal growth factor receptors in pulmonary adenocarcinoma. Anticancer Res 2010; 30: 5233-5237.
52. Simonetti S, Molina M, Queralt C, et al: Detection of EGFR mutations with mutationspecific antibodies in stage IV non-smallcell lung cancer. J Transl Med 2010; 8: 135.
53. Kawahara A, Azuma K, Sumi A, et al: Identification of non-small-cell lung cancer with activating EGFR mutations in malignant effusion and cerebrospinal fluid: rapid and sensitive detection of exon 19 deletion E746-A750 and exon 21 L858R mutation by immunocytochemistry. Lung Cancer 2011; 74: 35-40.
54. Mok T, Wu YL, Thongpraset S, et al: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Eng J Med 2009; 361: 947-957.
55. Hasanovic A, Ang D, Moreira AL, Zakowski MF: Use of mutation specific antibodies to detect EGFR status in small biopsy and cytology specimens of lung adenocarcinoma. Lung Cancer 2012; 77: 299-305.
56. Girard N, Sima CS, Jackman DM, Sequist LV, et al: Nomogram to predict the presence of EGFR activating mutation in lung adenocarcinoma. Eur Respir J 2012; 39: 366-372.
57. Bosdet I, Young SS, Ali RH, et al: Absence of TTF-1 immunoreactivity can predict EGFR wild-type in non-small cell lung cancer (NSCLC). Mod Pathol 2012; 25(suppl 2): 474A:1974.
58. Shiau CJ, Babwah J, da Cunha Santos G, et al: Selection of samples for epidermal growth factor receptor (EGFR) mutation analysis in non-squamous non-small cell lung carcinoma. Mod Pathol 2012; 25(suppl 2):490A:2045.
59. Chiarle R, Voena C, Ambrogio C, et al: The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat Rev Cancer 2008; 8: 11-23.
60. Inamura K, Takeuchi K, Togashi Y, et al: EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset. Mod Pathol 2009; 22: 508-515.
61. Inamura K, Takeuchi K, Togashi Y, et al: EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers. J Thorac Oncol 2008; 3: 13-17.
62. Rodig SJ, Mino-Kenudson M, Dacic S, et al: Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the Western population. Clin Cancer Res 2009; 15: 5216-5223.
63. Jokoji R, Yamasaki T, Minami S, et al: Combination of morphological feature analysis and immunohistochemistry is useful for screening of EML4-ALK-positive lung adenocarcinoma. J Clin Pathol 2010; 63: 1066-1070.
64. Shaw AT, Yeap BY, Mino-Kenudson M, et al: Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 2009; 27: 4247-4253.
65. Kwak EL, Bang YJ, Camidge DR, et al: Anaplastic lymphoma kinase inhibition in nonsmall-cell lung cancer. N Engl J Med 2010; 363: 1693-1703.
66. Shaw AT, Yeap BY, Solomon BJ, et al: Effect of crizotinib on overall survival in patients with advanced non-small cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol 2011; 12: 1004-1012.
67. Choi YL, Soda M, Yamashita Y, et al: EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med 2010; 363: 1734-1739.
68. Camidge DR, Kono SA, Flacco A, et al: Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment. Clin Cancer Res 2010; 16: 5581-5590.
69. Kim H, Yoo SB, Choe JY, et al: Detection of ALK gene rearrangement in non-small cell lung Cancer: a Comparison of fluorescence in situ hybridization and chromogenic in situ hybridization with correlation of ALK protein expression. J Thorac Oncol 2011; 6: 1359-1366.
70. Perner S, Wagner PL, Demichelis F, et al: EML4-ALK fusion lung cancer: a rare acquired event. Neoplasia 2008; 10: 298-302. (Pubitemid 351328588)
71. Martelli MP, Sozzi G, Hernandez L, et al: EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues. Am J Pathol 2009; 174: 661-670.
72. Paik JH, Choe G, Kim H, et al: Screening of anaplastic lymphoma kinase rearrangement by immunohistochemistry in non-small cell lung cancer: correlation with fluorescence in situ hybridization. J Thorac Oncol 2011; 6: 466-472.
73. Yi ES, Boland JM, Maleszewski JJ, et al: Correlation of IHC and FISH for ALK gene rearrangement in non-small cell lung carcinoma: IHC score algorithm for FISH. J Thorac Oncol 2011; 6: 459-465.
74. Mino-Kenudson M, Chirieac LR, Law K, et al: A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry. Clin Cancer Res 2010; 16: 1561-1571.
75. Sakairi Y, Nakajima T, Yasufuku K, et al: EML4-ALK fusion gene assessment using metastatic lymph node samples obtained by endobronchial ultrasound-guided transbronchial needle aspiration. Clin Cancer Res 2010; 16: 4938-4945.
76. Ang DC, Reinersman JM, Jhanwar SC, et al: Detection and clinicopathologic features of ALK rearranged lung Adenocarcinoma. Mod Pathol 2011; 24: 404A.